A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...
Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...
AllianceQUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery 24.10.2024 / 09:30 CET/CESTThe issuer is solely responsible for the content of this ...
Global Pleural Diseases Therapeutics Market to Reach USD 9.4 Billion by 2033, Growing at a 6.5% CAGR
Global Pleural Diseases Therapeutics MarketThe global market for pleural diseases therapeutics is projected to experience ...
Boehringer Ingelheim and GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced today a patient affordability initiative to provide citrate-free Adalimumab-adbm ...
One of the primary factors fueling the growth of the DOACs market is the rapid uptake and expected utilization within the ...
"Boehringer Ingelheim and Medidata have a responsibility to innovate for the benefit of patients," said Anthony Costello, chief executive of Medidata's Patient Cloud unit. "Together, we will be ...
Tracking patient response to DMARD therapy has the potential to improve remission, but multiple barriers must be overcome ...
FRANKFURT: The CEO of pharmaceuticals giant Roche, opens new tab said authorities should block the takeover of contract drug ...
Medpage Today on MSN3d
Potentially Large Cost Savings With Home-Based OCT for Neovascular AMDCHICAGO -- An artificial intelligence (AI)-based study of home monitoring for neovascular age-related macular degeneration ...
An interim analysis from a long-term open-label extension study has underlined the clinical efficacy and safety of ...
Boehringer Ingelheim had previously explored Ofev as a treatment for ... as having a high or low MeCo score at baseline based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback